OMER

Omeros Corp. stock has experienced significant events, including a 187.35% increase over the last six months. Key events include the FDA approval and U.S. launch of YARTEMLEA for HSCT-TMA, the assignment of a permanent reimbursement J-code for YARTEMLEA, and a strategic transaction with Novo Nordisk for zaltenibart, which included a $240 million upfront payment. The company reported a net income of $86.5 million for Q4 2025, driven by the zaltenibart transaction. However, the stock decreased by 17.7% from January 1st, 2026, to May 9, 2026.